Clinical Trial

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Study acronym: TRIM-EBC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-18; most recent amendment 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2024-11-26
Trial Details
NCT Number NCT06517212
Lead Sponsor Baylor Research Institute
Conditions Breast Cancer, Breast Neoplasms, Breast Cancers
Enrollment 48 participants
Start Date 2024-11-26
Primary Completion 2029-08-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-12